FGF23 and Myocardial fibrosis: Besides, our previous report has demonstrated that intra-myocardial injection of AAV-FGF23 in mice significantly worsened diastolic dysfunction and promoted myocardial fibrosis [28], which may contribute to renal damage in CRS.